Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment

Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain co...

Descripción completa

Detalles Bibliográficos
Autores: Rabiei Poor, Saghar, Ettcheto Arriola, Miren, Cano Fernández, Amanda, Sánchez-López, E. (Elena), Manzine, Patricia, Olloquequi, Jordi, Camins Espuny, Antoni, Javan, Mohammad
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/225337
Acceso en línea:https://hdl.handle.net/2445/225337
Access Level:acceso abierto
Palabra clave:Diabetis
Resistència a la insulina
Metformina
Malaltia d'Alzheimer
Diabetes
Insulin resistance
Metformin
Alzheimer's disease
id ES_893d9ec7049de6ce7b3d577b1b8690f1
oai_identifier_str oai:diposit.ub.edu:2445/225337
network_acronym_str ES
network_name_str España
repository_id_str
spelling Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatmentRabiei Poor, SagharEttcheto Arriola, MirenCano Fernández, AmandaSánchez-López, E. (Elena)Manzine, PatriciaOlloquequi, JordiCamins Espuny, AntoniJavan, MohammadDiabetisResistència a la insulinaMetforminaMalaltia d'AlzheimerDiabetesInsulin resistanceMetforminAlzheimer's diseaseAlzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain cognition, and eventually leading to neuronal death. Among them, obesity and type 2 diabetes mellitus (T2DM) have attracted increasing attention, since brain insulin resistance can contribute to neurodegeneration. Consequently, AD has been referred to “type 3 diabetes” and antidiabetic medications such as intranasal insulin, glitazones, metformin or liraglutide are being tested as possible alternatives. Metformin, a first line antihyperglycemic medication, is a 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator hypothesized to act as a geroprotective agent. However, studies on its association with age-related cognitive decline have shown controversial results with positive and negative findings. In spite of this, metformin shows positive benefits such as anti-inflammatory effects, accelerated neurogenesis, strengthened memory, and prolonged life expectancy. Moreover, it has been recently demonstrated that metformin enhances synaptophysin, sirtuin-1, AMPK, and brain-derived neuronal factor (BDNF) immunoreactivity, which are essential markers of plasticity. The present review discusses the numerous studies which have explored (1) the neuropathological hallmarks of AD, (2) association of type 2 diabetes with AD, and (3) the potential therapeutic effects of metformin on AD and preclinical models.MDPI2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/225337Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/ph14090890Pharmaceuticals, 2021, vol. 14, num.9https://doi.org/10.3390/ph14090890cc-by (c) Poor, S.R. et al., 2021http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2253372026-05-27T06:46:51Z
dc.title.none.fl_str_mv Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment
title Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment
spellingShingle Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment
Rabiei Poor, Saghar
Diabetis
Resistència a la insulina
Metformina
Malaltia d'Alzheimer
Diabetes
Insulin resistance
Metformin
Alzheimer's disease
title_short Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment
title_full Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment
title_fullStr Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment
title_full_unstemmed Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment
title_sort Metformin a potential pharmacological strategy in late onset Alzheimer's disease treatment
dc.creator.none.fl_str_mv Rabiei Poor, Saghar
Ettcheto Arriola, Miren
Cano Fernández, Amanda
Sánchez-López, E. (Elena)
Manzine, Patricia
Olloquequi, Jordi
Camins Espuny, Antoni
Javan, Mohammad
author Rabiei Poor, Saghar
author_facet Rabiei Poor, Saghar
Ettcheto Arriola, Miren
Cano Fernández, Amanda
Sánchez-López, E. (Elena)
Manzine, Patricia
Olloquequi, Jordi
Camins Espuny, Antoni
Javan, Mohammad
author_role author
author2 Ettcheto Arriola, Miren
Cano Fernández, Amanda
Sánchez-López, E. (Elena)
Manzine, Patricia
Olloquequi, Jordi
Camins Espuny, Antoni
Javan, Mohammad
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Diabetis
Resistència a la insulina
Metformina
Malaltia d'Alzheimer
Diabetes
Insulin resistance
Metformin
Alzheimer's disease
topic Diabetis
Resistència a la insulina
Metformina
Malaltia d'Alzheimer
Diabetes
Insulin resistance
Metformin
Alzheimer's disease
description Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effective treatments to stop the disease progression and it is becoming a major public health concern. Several risk factors are involved in the progression of AD, modifying neuronal circuits and brain cognition, and eventually leading to neuronal death. Among them, obesity and type 2 diabetes mellitus (T2DM) have attracted increasing attention, since brain insulin resistance can contribute to neurodegeneration. Consequently, AD has been referred to “type 3 diabetes” and antidiabetic medications such as intranasal insulin, glitazones, metformin or liraglutide are being tested as possible alternatives. Metformin, a first line antihyperglycemic medication, is a 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator hypothesized to act as a geroprotective agent. However, studies on its association with age-related cognitive decline have shown controversial results with positive and negative findings. In spite of this, metformin shows positive benefits such as anti-inflammatory effects, accelerated neurogenesis, strengthened memory, and prolonged life expectancy. Moreover, it has been recently demonstrated that metformin enhances synaptophysin, sirtuin-1, AMPK, and brain-derived neuronal factor (BDNF) immunoreactivity, which are essential markers of plasticity. The present review discusses the numerous studies which have explored (1) the neuropathological hallmarks of AD, (2) association of type 2 diabetes with AD, and (3) the potential therapeutic effects of metformin on AD and preclinical models.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/225337
url https://hdl.handle.net/2445/225337
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/ph14090890
Pharmaceuticals, 2021, vol. 14, num.9
https://doi.org/10.3390/ph14090890
dc.rights.none.fl_str_mv cc-by (c) Poor, S.R. et al., 2021
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Poor, S.R. et al., 2021
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412611763732481
score 15.223283

Similares en LA Referencia